Prognostic Impact of Tumor-Infiltrating Immune Cells on Efficacy of Neoadjuvant Chemotherapy in Patients with Advanced or Metastatic Ovarian Cancer: A Retrospective Study

Qunxian Rao; Miaoling Huang; Meimei Guan; Changhao Liu; Lijuan Wang; Zhongqiu Lin; Qing Chen

doi:10.12659/MSM.943170

17 July 2024 : Clinical Research

Prognostic Impact of Tumor-Infiltrating Immune Cells on Efficacy of Neoadjuvant Chemotherapy in Patients with Advanced or Metastatic Ovarian Cancer: A Retrospective Study

Qunxian Rao^1BCE, Miaoling Huang^1B, Meimei Guan^1C, Changhao Liu^1D, Lijuan Wang^1D, Zhongqiu Lin^1A*, Qing Chen^1A

DOI: 10.12659/MSM.943170

Med Sci Monit 2024; 30:e943170

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 4 Kaplan-Meier analysis of PFS by the density of intratumoral CD68+CD163− cells (A), stromal PD-1+ cells (B), stromal CD3+PD-1+ cells (C), and the positive rate of stromal CD3+PD-1+ cells (D). NACT – neoadjuvant chemotherapy; PFS – progression-free survival. Figure 4 was plotted by GraphPad Prims version 8 (https://www.graphpad.com/).

Back to the Article

Prognostic Impact of Tumor-Infiltrating Immune Cells on Efficacy of Neoadjuvant Chemotherapy in Patients with Advanced or Metastatic Ovarian Cancer: A Retrospective Study

Your Privacy